ENXTPA:DBVBiotechs
Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
ENXTPA:ALNOVBiotechs
Is Novacyt (EPA:ALNOV) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
ENXTPA:ALVALBiotechs
Valbiotis SA (EPA:ALVAL): Are Analysts Optimistic?
Valbiotis SA ( EPA:ALVAL ) is possibly approaching a major achievement in its business, so we would like to shine some...
ENXTPA:VLABiotechs
Valneva Third Quarter 2023 Earnings: Misses Expectations
Valneva ( EPA:VLA ) Third Quarter 2023 Results Key Financial Results Revenue: €38.1m (down 76% from 3Q 2022). Net loss...
ENXTPA:OSEBiotechs
Further weakness as OSE Immunotherapeutics (EPA:OSE) drops 11% this week, taking three-year losses to 54%
It is a pleasure to report that the OSE Immunotherapeutics SA ( EPA:OSE ) is up 51% in the last quarter. But that...
ENXTPA:ALCLSBiotechs
Retail investors who hold 36% of Cellectis S.A. (EPA:ALCLS) gained 207%, institutions profited as well
Key Insights Cellectis' significant retail investors ownership suggests that the key decisions are influenced by...
ENXTPA:ALQGCBiotechs
Quantum Genomics Société Anonyme (EPA:ALQGC): When Will It Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at Quantum Genomics Sociét...
ENXTPA:ADOCBiotechs
Adocia SA's (EPA:ADOC) market cap dropped €13m last week; Retail investors bore the brunt
Key Insights The considerable ownership by retail investors in Adocia indicates that they collectively have a greater...
ENXTPA:IVABiotechs
Shareholders in Inventiva (EPA:IVA) have lost 71%, as stock drops 12% this past week
It's not possible to invest over long periods without making some bad investments. But really big losses can really...
ENXTPA:DBVBiotechs
Hedge funds owners may consider drastic measures as DBV Technologies S.A.'s (EPA:DBV) recent €27m drop adds to long-term losses
Key Insights Significantly high institutional ownership implies DBV Technologies' stock price is sensitive to their...
ENXTPA:VLABiotechs
Valneva SE's (EPA:VLA) stock price dropped 10% last week; individual investors would not be happy
Key Insights Valneva's significant individual investors ownership suggests that the key decisions are influenced by...
ENXTPA:ALERSBiotechs
Eurobio Scientific Société anonyme's (EPA:ALERS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Eurobio Scientific Société anonyme (EPA:ALERS) has had a rough month with its share price down 11%. However, the...
ENXTPA:ABNXBiotechs
Is ABIONYX Pharma (EPA:ABNX) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
ENXTPA:NANOBiotechs
Despite currently being unprofitable, Nanobiotix (EPA:NANO) has delivered a 64% return to shareholders over 1 year
It certainly might concern Nanobiotix S.A. ( EPA:NANO ) shareholders to see the share price down 31% in just 30 days...
ENXTPA:OSEBiotechs
We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
ENXTPA:IPHBiotechs
Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Innate Pharma S.A. ( EPA:IPH ) shareholders will have a reason to smile today, with the analysts making substantial...
ENXTPA:POXELBiotechs
Poxel Reports First Half 2023 Earnings
Poxel ( EPA:POXEL ) First Half 2023 Results Key Financial Results Net loss: €26.2m (loss widened by 96% from 1H 2022...
ENXTPA:ALGENBiotechs
genOway Société anonyme Reports First Half 2023 Earnings
genOway Société anonyme ( EPA:ALGEN ) First Half 2023 Results Key Financial Results Revenue: €9.33m (down 6.7% from 1H...
ENXTPA:TNGBiotechs
Insiders are the top stockholders in Transgene SA (EPA:TNG), and the recent 15% drop might have disappointed them
Key Insights Significant insider control over Transgene implies vested interests in company growth 60% of the company...
ENXTPA:ALGENBiotechs
We Think genOway Société anonyme (EPA:ALGEN) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
ENXTPA:GNFTBiotechs
Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
ENXTPA:ALPATBiotechs
We Might See A Profit From Plant Advanced Technologies SA (EPA:ALPAT) Soon
With the business potentially at an important milestone, we thought we'd take a closer look at Plant Advanced...
ENXTPA:ADOCBiotechs
Adocia Reports First Half 2023 Earnings
Adocia ( EPA:ADOC ) First Half 2023 Results Key Financial Results Revenue: €3.90m (down 63% from 1H 2022). Net loss...
ENXTPA:ALACTBiotechs
Acticor Biotech SAS (EPA:ALACT) Could Be Less Than A Year Away From Profitability
We feel now is a pretty good time to analyse Acticor Biotech SAS' ( EPA:ALACT ) business as it appears the company may...